DLBCL-1
Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial
Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival
Actionable Insights Powered by AI
Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival